288 related articles for article (PubMed ID: 22348000)
1. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.
Granich R; Kahn JG; Bennett R; Holmes CB; Garg N; Serenata C; Sabin ML; Makhlouf-Obermeyer C; De Filippo Mack C; Williams P; Jones L; Smyth C; Kutch KA; Ying-Ru L; Vitoria M; Souteyrand Y; Crowley S; Korenromp EL; Williams BG
PLoS One; 2012; 7(2):e30216. PubMed ID: 22348000
[TBL] [Abstract][Full Text] [Related]
2. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
3. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
[TBL] [Abstract][Full Text] [Related]
6. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
7. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
8. Impact and Cost-Effectiveness of Point-Of-Care CD4 Testing on the HIV Epidemic in South Africa.
Heffernan A; Barber E; Thomas R; Fraser C; Pickles M; Cori A
PLoS One; 2016; 11(7):e0158303. PubMed ID: 27391129
[TBL] [Abstract][Full Text] [Related]
9. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
[TBL] [Abstract][Full Text] [Related]
12. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.
Eaton JW; Johnson LF; Salomon JA; Bärnighausen T; Bendavid E; Bershteyn A; Bloom DE; Cambiano V; Fraser C; Hontelez JA; Humair S; Klein DJ; Long EF; Phillips AN; Pretorius C; Stover J; Wenger EA; Williams BG; Hallett TB
PLoS Med; 2012; 9(7):e1001245. PubMed ID: 22802730
[TBL] [Abstract][Full Text] [Related]
13. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
[TBL] [Abstract][Full Text] [Related]
15. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
Dutta A; Barker C; Kallarakal A
PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
[TBL] [Abstract][Full Text] [Related]
16. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis.
Ciaranello AL; Myer L; Kelly K; Christensen S; Daskilewicz K; Doherty K; Bekker LG; Hou T; Wood R; Francke JA; Wools-Kaloustian K; Freedberg KA; Walensky RP
PLoS One; 2015; 10(3):e0117751. PubMed ID: 25756498
[TBL] [Abstract][Full Text] [Related]
17. Economics of antiretroviral treatment vs. circumcision for HIV prevention.
Bärnighausen T; Bloom DE; Humair S
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21271-6. PubMed ID: 23223563
[TBL] [Abstract][Full Text] [Related]
18. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.
Hontelez JA; de Vlas SJ; Tanser F; Bakker R; Bärnighausen T; Newell ML; Baltussen R; Lurie MN
PLoS One; 2011; 6(7):e21919. PubMed ID: 21799755
[TBL] [Abstract][Full Text] [Related]
19. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
Wilkinson D; Floyd K; Gilks CF
S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
[TBL] [Abstract][Full Text] [Related]
20. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.
Marseille E; Giganti MJ; Mwango A; Chisembele-Taylor A; Mulenga L; Over M; Kahn JG; Stringer JS
PLoS One; 2012; 7(12):e51993. PubMed ID: 23284843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
